Justera Health Valuation

Is VTAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VTAL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VTAL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTAL?

Key metric: As VTAL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VTAL. This is calculated by dividing VTAL's market cap by their current revenue.
What is VTAL's PS Ratio?
PS Ratio	0.8x
Sales	CA$1.91m
Market Cap	CA$804.03k

VTAL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.5x
Enterprise Value/EBITDA	-0.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does VTAL's PS Ratio compare to its peers?

The above table shows the PS ratio for VTAL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.4x
NEWU Newtopia	0.1x	n/a	CA$866.3k
DELC Delic Holdings	0.08x	n/a	CA$691.5k
OMND Optimind Pharma	4.9x	n/a	CA$548.9k
BRAX Braxia Scientific	0.6x	n/a	CA$1.4m
VTAL Justera Health	0.8x	n/a	CA$804.0k

Price-To-Sales vs Peers: VTAL is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does VTAL's PS Ratio compare vs other companies in the CA Healthcare Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
DOC CloudMD Software & Services	0.1x	n/a	US$7.82m
NPTH NeuPath Health	0.1x	n/a	US$6.86m
PHA Premier Health of America	0.05x	4.3%	US$5.56m
BLMH Bloom Health Partners	0.1x	n/a	US$2.85m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: VTAL is good value based on its Price-To-Sales Ratio (0.8x) compared to the North American Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is VTAL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTAL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VTAL's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Andlauer Healthcare Group

CA$1.7b

A supply chain management company, provides a platform of customized third-party logistics (3PL) and specialized transportation solutions for the healthcare sector in Canada and the United States.

AND

CA$42.64

-0.8%

9.6%

NeuPath Health

CA$9.6m

Provides chronic pain management services in Canada.

NPTH

CA$0.17

3.0%

9.7%

Hamilton Thorne

CA$346.3m

Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets.

HTL

CA$2.24

0.4%

77.8%